Researchers
Barrett, Lindy Elise PHD
Broad Institute of MIT and Harvard
INCLUDE Grants
Establishing foundational tools and datasets for investigation of NSD1 gene function in neural development
Grant Number
R03TR004561
NIH Institute
NCATS
Mechanism
R03
This project proposes to develop novel human induced pluripotent stem cell (iPSC) tools to study NSD1 haploinsufficiency and to generate pilot data on NSD1 molecular function in human neurons. These tools and datasets will be used to accelerate our understanding of how NSD1 haploinsufficiency drives the neurodevelopmental phenotypes observed in Sotos syndrome.
Investigating epigenetic mechanisms in Down syndrome using human cellular models
Grant Number
R01HD111876
NIH Institute
NICHD
Mechanism
R01
This project uses human induced pluripotent stem cell (iPSC) models to investigate the novel hypothesis that dysregulation of histone modifications in Down syndrome (DS) drives downstream molecular and cellular phenotypes. In addition to elucidating fundamental mechanisms of epigenetic re-wiring in DS, this project will explore a set of key unanswered questions in the field, and test the utility of epigenetic modifiers for normalizing histone phenotypes which has the exiting potential to illuminate new therapeutic targets.
Dissecting the role of FMRP in RNA processing using hPSC models
Grant Number
R01HD101534
NIH Institute
NICHD
Mechanism
R01
The goal of this proposal is to elucidate fundamental molecular mechanisms of the RNA binding protein FMRP in relevant human cell types. Our preliminary data show that FMRP binds pre-mRNA targets in human embryonic stem cells and excitatory cortical neurons, and we will now test as series of hypotheses regarding FMRP’s role in RNA processing. As loss of FMRP is causative for Fragile X syndrome, these data have important implications for human disease biology.
Delineating a role for histone modifications in Down syndrome using human cellular models
Grant Number
3R01HD101534-01A1S1
NIH Institute
NICHD
Mechanism
R01
This project investigates epigenetic dysregulation in Down Syndrome using human induced pluripotent stem cell (iPSC) models. In addition to uncovering basic mechanisms of Down syndrome that overlap with other neurodevelopmental disorders, epigenetic modifiers are an active area of therapeutic development and we speculate these data could uncover novel, clinically relevant targets for Down syndrome patients.